60112-28-9

Usage

Uses

Used in Flavor and Fragrance Industry:
(E)-METHYL 4-CYCLOHEXYL-4-OXOBUT-2-ENOATE is used as a flavor and fragrance ingredient for its fruity odor, enhancing the sensory experience in various consumer products.
Used in Pharmaceutical Synthesis:
(E)-METHYL 4-CYCLOHEXYL-4-OXOBUT-2-ENOATE is used as a key intermediate in the synthesis of pharmaceuticals, contributing to the development of new medications.
Used in Agrochemical Production:
(E)-METHYL 4-CYCLOHEXYL-4-OXOBUT-2-ENOATE is also utilized as an intermediate in the production of agrochemicals, playing a role in the development of agricultural products.
Used in Perfume Production:
(E)-METHYL 4-CYCLOHEXYL-4-OXOBUT-2-ENOATE is used as a component in the production of perfumes, adding to the complexity and appeal of fragrances.
Used in Cosmetics Manufacturing:
(E)-METHYL 4-CYCLOHEXYL-4-OXOBUT-2-ENOATE is used as an ingredient in the cosmetics industry, where it contributes to the formulation of various cosmetic products.
Used in Food Product Development:
(E)-METHYL 4-CYCLOHEXYL-4-OXOBUT-2-ENOATE is used in the food industry, particularly in the development of flavors and scents for a diverse range of food products.

Upstream product

• 2863-48-1 1-cyclohexyl-2-(methylsulfinyl)ethanone 
• 96-32-2 bromoacetic acid methyl ester 
• 823-76-7 Cyclohexyl methyl ketone 
• 67-56-1 methanol 
• 112895-82-6 trans-β-hexahydrobenzoylacrylic acid 

Relevant academic research and scientific papers

Design, synthesis, and bioevaluation of a novel class of (E)-4-oxo-crotonamide derivatives as potent antituberculosis agents

A series of novel (E)-4-oxo-2-crotonamide derivatives were designed and synthesized to find potent antituberculosis agents. All the target compounds were evaluated for their in vitro activity against Mycobacterium tuberculosis H37Rv(MTB). Results reveal that 4-phenyl moiety at part A and short methyl group at part C were found to be favorable. Most of the derivatives displayed promising activity against MTB with MIC ranging from 0.125 to 4 μg/mL. Especially, compound IIIa16 was found to have the best activity with MIC of 0.125 μg/mL against MTB and with MIC in the range of 0.05–0.48 μg/mL against drug-resistant clinical MTB isolates.

Substituted 4-oxo-crotonic acid derivatives as a new class of protein kinase B (PknB) inhibitors: synthesis and SAR study

Protein kinase B (PknB) is an essential serine/threonine protein kinase required for Mycobacterium tuberculosis (M. tb) cell division and cell-wall biosynthesis. A high throughput screen using PknB identified a (E)-4-oxo-crotonic acid inhibitor, named YH-8, which was used as a scaffold for SAR investigations. A significant improvement in enzyme affinity was achieved. The results indicated that the α,β-unsaturated ketone scaffold and “trans-” configuration are essential for the activity against PknB. And compounds with an aryl group, especially with electron-withdrawing substituents on benzene ring, exhibited four fold potency than that of YH-8.

Antidiabetic pyrrolecarboxylic acids

Certain pyrrolecarboxylic and pyrroleacetic acid derivatives substituted on the pyrrole ring with thioether groups, acyl groups, phenyl, substituted phenyl, phenoxy, substituted phenoxy, benzyl or halo and optionally substituted on the pyrrole nitrogen with alkyl, and the pharmaceutically acceptable salts thereof, are useful in lowering the blood glucose levels of hyperglycemic animals.